Nose drops of pneumonia bacteria could pave way for better vaccines
NCT ID NCT05535868
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This study investigates how a specific strain of pneumococcus bacteria (serotype 3) colonizes the nose of healthy adults. Researchers will give volunteers nose drops containing the bacteria to see what dose leads to colonization and how long the bacteria stay before the immune system clears them. The goal is to develop a reliable model for testing future vaccines against pneumococcal infections.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Serotype 3 pneumococcal bacteria (nose drops)
- What this could lead to
- If successful, this model could help researchers test new vaccines that prevent pneumococcal infections more effectively.
- What could go wrong
- This is an early-stage model study, not a treatment trial. It may not translate into real-world vaccine success, and some participants may experience temporary nasal colonization.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONTROLLED HUMAN INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Liverpool School of Tropical Medicine
Liverpool, L7 8XZ, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.